1) King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015年;12(6):335–43.
2) Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, ほか. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014 年;384(9938):164–72.
3) B. Chevallier, H. Roche, J.P. Olivier, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993年;16:223–8.
4) 一般社団法人 日本乳癌学会. 臨床・病理 乳癌取り扱い規約. 18th版. 2018.
5) 日本乳癌学会. 乳癌診療ガイドライン 1 治療編 2018年版. 第4版. 2018.
6) von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, ほか. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol. 2012 年;30(15):1796–804.
7) Park CC, Schnitt SJ. Outcome at 8 Years After Breast-Conserving Surgery and Radiation Therapy for Invasive Breast Cancer: Influence of Margin Status and Systemic Therapy on Local Recurrence. J Clin Oncol2000. 18(8):1668–75.
8) Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, Pereira J, ほか. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ. 2012年;345(jul12 2):e4505–e4505.
9) von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, ほか. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019年;380(7):617–28.
10) Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, ほか. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017年;376(22):2147–59.
11) American college of Radiology. Breast imaging reporting and data system (BI- RADS). 5th ed. Reston. 2013.
12) Kim H, Kim HH, Park JS, Shin HJ, Cha JH, Chae EY, ほか. Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection. Br J Radiol. 2014年;87(1043):20140142.
13) Choi BB, Kim SH. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Acta Radiol. 2015 年;56(7):790–7.
14) Rieber A, Zeitler H, Rosenthal H, Görich J, Kreienberg R, Brambs HJ, ほか. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997年;70(833):452–8.
15) Leddy R, Irshad A, Metcalfe A, Mabalam P, Abid A, Ackerman S, ほか. Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: Is the accuracy affected by breast density or cancer subtype? J Clin Ultrasound JCU. 2015年;44.
16) Lehman CD, Hendrick RE, Maki DD, Schnall MD. MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast Cancer. N Engl J Med. 2007年;9.
17) Behjatnia B, Sim J, Bassett LW, Moatamed NA, Apple SK. Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. :7.
18) Mennella S, Garlaschi A, Paparo F, Perillo M, Celenza M, Massa T, ほか. Magnetic resonance imaging of breast cancer: factors affecting the accuracy of preoperative lesion sizing. Acta Radiol. 2015年;56(3):260–8.
19) Lobbes MBI. Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Res Treat. 2012年;136(1):313–4.
20) Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP,ほか. Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy. JNCI J Natl Cancer Inst. 2013年;105(5):321–33.
21) Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, ほか. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015年;15(1):662.
22) De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, ほか. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. 2013年;119(10):1776–83.
23) Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G,ほか . Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004年;14(8). [Internet]. http://link.springer.com/10.1007/s00330-004-2246-z [参照 2020年8月3日]
24) Rieber A, Brambs H-J, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002年;12(7):1711–9.
25) Kim S-Y, Cho N, Park I-A, Kwon BR, Shin SU, Kim SY, ほか. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy. Radiology. 2018年;289(2):327–34.
26) Mann RM, Mus RD, van Zelst J, Geppert C, Karssemeijer N, Platel B. A Novel Approach to Contrast-Enhanced Breast Magnetic Resonance Imaging for Screening: High-Resolution Ultrafast Dynamic Imaging. Invest Radiol. 2014年;49(9):579–85.
27) Abe H, Mori N, Tsuchiya K, Schacht DV, Pineda FD, Jiang Y, ほか. Kinetic Analysis of Benign and Malignant Breast Lesions With Ultrafast Dynamic Contrast-Enhanced MRI: Comparison With Standard Kinetic Assessment. Am J Roentgenol. 2016 年;207(5):1159–66.
28) Mori N, Abe H, Mugikura S, Takasawa C, Sato S, Miyashita M, ほか. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density. Acad Radiol. 2019年;26(7):e141–9.
29) Pineda FD, Medved M, Wang S, Fan X, Schacht DV, Sennett C, ほか. Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Acad Radiol. 2016年;23(9):8.
30) Mori N, Pineda FD, Tsuchiya K, Mugikura S, Takahashi S, Karczmar GS, ほか. Fast Temporal Resolution Dynamic Contrast-Enhanced MRI: Histogram Analysis Versus Visual Analysis for Differentiating Benign and Malignant Breast Lesions. Am J Roentgenol. 2018年;211(4):933–9.
31) Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Newstead GM. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: A sensitivity and specificity study. Magn Reson Med. 2008年;59(4):747–54.
32) Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977年;33(1):159.
33) Yeap BH, Muniandy S, Lee S-K, Sabaratnam S, Singh M. Specimen Shrinkage and Its Influence on Margin Assessment in Breast Cancer. Asian J Surg. 2007年;30(3):183–7.
34) Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR Imaging for Revealing Residual Breast Cancer in Patients Who Have Undergone Neoadjuvant Chemotherapy. Am J Roentgenol. 2002年;179(5):1193–9.
35) Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey, Taydas O, Durhan G, Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey, Akpinar MG, Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey, ほか. Comparison of MRI and US in Tumor Size Evaluation of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Eur J Breast Health. 2019年;15(2):119–24.
36) Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, ほか. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007年;96(6):474–80.